… The relative contribution of viral damage and of innate and adaptive immune responses
in course of COVID-19 greatly varies over time (31–33). In the early phases, common to all …

… A very recent study showed that this antiviral, originally developed against Ebola hemorrhagic
fever, slightly reduces the recovery time of patients hospitalized with Covid-19 (15 to 11 …

… As viral infections are an increasing threat to human societies, the need for new therapeutic
strategies is becoming even more obvious. As no vaccine is available for COVID-19, the …

… A clinical trial is ongoing at the present time to test an antiC5 antibody … COVID-19, at the
present time. Nevertheless, the idea of using TNF blockers to treat patients with severe COVID-…

… The 2020 coronavirus epidemic is characterized by high infectious rates and relatively high
… to the COVID-19 infection [1,2]. In most of those severe cases of coronavirus infection, the …

… COVID-19 drug development and highlight important unmet needs. We examine key therapeutic
… Regrettably, the important timing of therapy administration within relevant windows of …

… coronavirus that causes COVID-19, has brought together scientists in the quest for possible
therapeutic … new drugs to manage COVID-19 effectively is a challenging and time-consuming …

… Drug repurposing is the best approach to recognize therapeutic options for COVID‑19 in
a limited time [14, 15]. The great benefit of this approach is the available science about the …

… The Therapeutics Clinical Working Group … therapeutic candidates for COVID-19 with near-term
potential. The goals have been to prioritize and test potential therapeutic agents for COVID…

… of coronavirus disease 2019 (COVID-19) has been challenging to define with the emergence
of new symptoms with time. The most common clinical manifestations of COVID-19 include …